A priori quality assurance using a benchmark case of the randomized phase 2 GORTEC 2014-14 in oligometastatic head and neck cancer patients.

Date publication

septembre 2021

Journal

Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique

Auteurs

Membres identifiés du Cancéropôle Est :
Dr GUIHARD Sébastien

Tous les auteurs :
Khalladi N, Dejean C, Bosset M, Pointreau Y, Kinj R, Racadot S, Castelli J, Huguet F, Renard S, Guihard S, Tao Y, Rouvier JM, Johnson A, Bourhis J, Xu Shan S, Thariat J

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/34565664

Résumé

A Benchmark Case (BC) was performed as part of the quality assurance process of the randomized phase 2 GORTEC 2014-14 OMET study, testing the possibility of multisite stereotactic radiation therapy (SBRT) alone in oligometastatic head and neck squamous cell carcinoma (HNSCC) as an alternative to systemic treatment and SBRT.

Mots clés

Assurance qualité, Benchmark case, Cancer, Clinical trial, Deviation, Déviation, Essai clinique, Head and neck, ORL, Quality assurance, Radiothérapie stéréotaxique, Stereotactic radiotherapy

Référence

Cancer Radiother. 2021 Sep 23;: